Highlights and Quick Summary
- Notes Payable for the quarter ending December 30, 2017 was $126 Million (a 0.92% increase compared to previous quarter)
- Year-over-year quarterly Notes Payable increased by 2.75%
- Annual Notes Payable for 2017 was $126 Million (a -28.17% decrease from previous year)
- Annual Notes Payable for 2014 was $175 Million (a -45.31% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Notes Payable of PDL BioPharma, Inc.Most recent Notes Payableof PDLI including historical data for past 10 years.
Interactive Chart of Notes Payable of PDL BioPharma, Inc.
PDL BioPharma, Inc. Notes Payable for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of PDL BioPharma, Inc.
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.